Arlin French, DO
Ophthalmology · Clarkston, MINPI 1538154125
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Alcon at 44.8% of the total. Reporting peaked in 2022 at $1,065 and has fallen 66.7% since, to $354 in 2025.
Across 103 payments — averaging $36.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Johnson & Johnson Surgical Vision, Inc.$226
- Carl Zeiss Meditec USA, Inc.$189
- NEW World Medical,inc.$182
- Rxsight Inc$181
- Ocular Therapeutix, Inc.$156
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,69999%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 30 | $1,671 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $226 |
| Carl Zeiss Meditec USA, Inc. | 1 | $189 |
| NEW World Medical,inc. | 4 | $182 |
| Rxsight Inc | 4 | $181 |
| Ocular Therapeutix, Inc. | 5 | $156 |
| Sight Sciences, Inc. | 1 | $150 |
| Glaukos Corporation | 6 | $140 |
| AbbVie(2 entities) | 7 | $126 |
| Tarsus Pharmaceuticals, Inc. | 4 | $96 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $89 |
| Sun Pharmaceutical Industries Inc. | 5 | $86 |
| Biotissue Holdings Inc. | 4 | $73 |
| Amgen | 3 | $66 |
| Bausch & Lomb Americas Inc. | 4 | $65 |
| Oyster Point Pharma, Inc. | 3 | $55 |
| Dompe US, Inc. | 2 | $36 |
| Novartis | 2 | $35 |
| Johnson & Johnson | 2 | $34 |
| Aerie Pharmaceuticals, Inc. | 2 | $25 |
| Thea Pharma Inc. | 1 | $22 |
| Beaver-visitec International, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$358
- CLARUS$189
- OMNI(R) SURGICAL SYSTEM (US)$150
- ReSTOR$143
- RXSIGHT CONTACT LENS$142
- RXSIGHT INJECTOR CARTRIDGE$142
- RXSIGHT INJECTOR HANDPIECE$142
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$142
- LIGHT ADJUSTABLE LENS (LAL)$142
- Ahmed Glaucoma Valve$129
- Kahook Dual Blade$129
- DEXTENZA$129
- Tecnis IOL$126
- CATALYS SYSTEM$126
- Hydrus Microstent$125
- PanOptix$123
- LenSx$119
How this compares
$3,735 in reported general payments places this provider in the 80th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 57 | $68,709 |
| LumiganBimatoprost | 63 | $29,641 |
| Timolol Maleate | 199 | $11,654 |
| Prednisolone Acetate | 322 | $11,000 |
| Bromfenac Sodium | 40 | $10,505 |
| Cyclosporine | 17 | $8,808 |
| Latanoprost | 419 | $8,540 |
| ProlensaBromfenac Sodium | 24 | $8,341 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 29 | $5,266 |
| Brimonidine Tartrate | 56 | $3,062 |
| Ofloxacin | 185 | $2,089 |
| Travoprost | 11 | $1,815 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 54 | $754 |
| ValacyclovirValacyclovir Hcl | 11 | $697 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $126 | $98,350120 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $89 | $8,34124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 674 ophthalmology providers in Michigan.
Other ophthalmology in Clarkston
- Manjool ShahAnn Arbor$609K
- Gregory KatzYpsilanti$401K
- Timothy PageBirmingham$250K
- David ZacksAnn Arbor$177K
- Scott WesthouseGrand Rapids$138K
- Bret HughesDetroit$123K
- Pradeepa YoganathanDetroit$115K
- Jason MillerAnn Arbor$104K
- David TukelDearborn$91K
- Yannis PaulusAnn Arbor$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.